The announcement means the company will be pulling the plug on the CardinALS trial after its ALS drug failed to halt disease ...

But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show if twice daily oral dosing of ...

Philadelphia dad Eric Brunner was diagnosed with amyotrophic lateral sclerosis, the fatal disease known as ALS. He wants to ...

PTC Therapeutics may reeling from the failure of its amyotrophic lateral sclerosis (ALS) drug utreloxastat yesterday, but the ...

In a new study of mouse cells, scientists found that both the biochemical and mechanical effects of exercise may help injured ...

PTC Therapeutics halts Utreloxastat development after ALS trial disappoints. Analysts highlight promising pipeline, including ...

A team from IIT-BHU is developing a revolutionary cell-based device using 3D bioprinting technology to potentially cure ...

Bank of America Securities analyst Tazeen Ahmad maintained a Sell rating on PTC Therapeutics (PTCT – Research Report) yesterday and set a price ...

The company’s oral, microbiome-changing therapy was well tolerated in patients with amyotrophic lateral sclerosis.

Widetrial is supporting an expanded access program (EAP) to bring MN-166 (ibudilast) to ALS patients ineligible for clinical ...

There are now at least two patients who have had Neuralink's brain chip implanted in their head. While there have been some ...

A team at IIT (BHU) is developing a revolutionary cell-based medical device using 3D bioprinting technology aimed at curing ...